Page 13 - Abivax News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Once-daily oral treatment was well-tolerated and demonstrated a good safety profile in Phase IIb study - News - PharmaTimes

ABIVAX Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy DGAP-News: ABIVAX / Key word(s): Study Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy 05.03.2021 / 20:00 Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial  due to lack of efficacy The Data Safety and Monitoring Board (DSMB) confirmed ABX464 was safe and well tolerated in 383 high-risk Covid-19 patients Lower than expected rate (10.1%) of progression to severe disea...

ABIVAX Abivax publishes data of ABX464 induction and long-term maintenance phase 2a ulcerative colitis study in the prestigious journal 'Gastroenterology' DGAP-News: ABIVAX / Key word(s): Miscellaneous Abivax publishes data of ABX464 induction and long-term maintenance phase 2a ulcerative colitis study in the prestigious journal 'Gastroenterology' 03.03.2021 / 18:30 The issuer is solely responsible for the content of this announcement. Abivax publishes data of ABX464 induction and long-term maintenance phase 2a ulcerative colitis study in the prestigious journal "Gastroenterology" Peer-revie...

DGAP-News: ABIVAX / Key word(s): Personnel Abivax appoints Dr Sophie Biguenet, M.D., as Chief Medical Officer 01.03.2021 / 18:00 Abivax Chief Medical Officer Dr Sophie Biguenet joins Abivax on March 1 As CMO, Sophie Biguenet will drive Abivax's main clinical program of ABX464 for the treatment of inflammatory bowel diseases (IBD) into phase 3 testing in 2021 PARIS, March 1, 2021 - 06:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company modulating the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer...